Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

Purpose The role of cetuximab in the treatment of locoregionally advanced head and neck
squamous cell cancer (LA-HNSCC) remains poorly defined. In this phase 2 randomized …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Background We investigated the tolerability of cetuximab plus radiotherapy in Japanese
patients with untreated locally advanced squamous cell carcinoma of the head and neck …

Purpose To determine the potential efficacy of combining cetuximab with chemotherapy in
patients with advanced nodal disease, we conducted a phase II trial with induction …

Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

Background Intensification of chemoradiation for advanced head and neck squamous cell
carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy …

Purpose This study describes the long-term survival and toxicity outcomes of a multicenter
randomized phase 2 trial comparing radiation therapy (RT) plus cisplatin (CDDP) or …

Objective. To review the current state of the data on the use of cetuximab in head and neck
squamous cell carcinoma (HNSCC). Data Sources. The National Center for Biotechnology …